Earnings ·
Co-Diagnostics reports Q3 revenue of $0.3M and net loss of $6.3M; raises up to $3.1M in convertible debt
CODXCo-Diagnostics, Inc.
Co-Diagnostics reported third-quarter 2026 revenue of $0.3 million, compared to $0.1 million in the prior-year period, with operating expenses declining 12% year-over-year to $6.2 million. The company posted a net loss of $6.3 million, or $1.01 per share, against a $5.9 million loss previously. Cash and cash equivalents stood at $0.7 million as of September 30, 2026. Subsequent to the quarter end, Co-Diagnostics completed a senior secured convertible debt financing with J.J. Astor & Co., receiving approximately $2.1 million in initial funding, with up to an additional $1.0 million available subject to specified conditions. The company also highlighted regulatory submissions for Flu A/B & RSV and tuberculosis tests under review by the FDA and CDSCO respectively. Co-Diagnostics is a molecular diagnostics company that develops, manufactures and markets state-of-the-art diagnostics technologies.